The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2022
Filed:
Oct. 26, 2017
Applicant:
Leap Therapeutics, Inc., Cambridge, MA (US);
Inventors:
Michael H. Kagey, Arlington, MA (US);
Cynthia A. Sirard, Cambridge, MA (US);
Assignee:
Leap Therapeutics, Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 45/06 (2006.01); C12Q 1/6886 (2018.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 31/337 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12Q 1/6886 (2013.01); A61K 2039/505 (2013.01); A61K 2039/55 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract
A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.